# Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major

> **NCT02342145** · PHASE4 · COMPLETED · sponsor: **Zhongming Zhang** · enrollment: 205 (actual)

## Conditions studied

- Beta-Thalassemia Major
- Graft-versus-host Disease (GVHD)

## Interventions

- **DRUG:** Basiliximab,
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT02342145
- **Lead sponsor:** Zhongming Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2022-08-20
- **Final completion:** 2022-08-20
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342145, "Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02342145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*